a b s t r a c tThe gold standard for treatment of upper urinary tract urothelial carcinoma remains nephroureterectomy with the ipsilateral bladder cuff excision. With the introduction of robot system, robot-assisted surgery has become popular in the management of urological malignancies. We report a single institute experience of robot-assisted nephroureterectomy (RANU) for the treatment of upper urinary tract urothelial carcinoma (UC) without re-docking the robot system or reposition of the patient. The perioperative and oncologic outcomes are discussed.

No abstract

Aim: To evaluate the oncological outcomes of pathological T3a upstaging from clinical T1 renal cell carcinoma. Patients and Methods: We retrospectively studied patients who underwent radical or partial nephrectomy for clinical T1 renal tumors. Results: The median follow-up period was 44 months. At three and five years, the respective overall survival rate was 88. 7% and 82.4% in pT3a disease, 95.7% and 93.4% in pT1 (p=0.008), the cancer-specific survival rate, 93.9% and 90.8% in pT3a, 99% and 97.7% in pT1 (p=0.001), and the recurrence-free survival rate, 79.7% and 71.0% in pT3a, and 95.5 and 94.3% in pT1 (p<0.001). Conclusion: Patients with pathological T3a upstaging tumors were associated with a significantly decreased survival rate, along with a higher recurrence rate when compared to those with pathological T1 disease. 799Lai et al: Survival Αnalysis of Upstaging pT3a RCC

No abstract

No abstract